FDA grants IND clearance for Adicet Bio's renal cell carcinoma treatment trial [Yahoo! Finance]
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Yahoo! Finance
a Phase I clinical trial of ADI-270 for relapsed or refractory renal cell carcinoma (r/r RCC). ADI-270 is an armoured allogeneic 'off-the-shelf' gamma delta chimeric antigen receptor (CAR) T-cell therapy candidate that is designed to treat CD70+ cancers. The prospective, multicentre, open-label trial is set to begin in the second half of this year to evaluate the drug's safety and anti-tumour activity in adults with clear cell r/r RCC. Following lymphodepletion, participants will be given a single dose of ADI-270 with 3E8 CAR-positive cells, with the potential for a second dose based on specific criteria outlined in the study protocol. The trial will have dose escalation and expansion phases to assess the therapy's safety, tolerability and pharmacokinetics. It will also measure anti-tumour activity using metrics such as overall response rate, duration of response and disease control rate. Adicet Bio president and CEO Chen Schor said: “ADI-270 is the first ever gamma delta
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaBusiness Wire
- We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
ACET
Earnings
- 5/14/24 - In-Line
ACET
Sec Filings
- 6/24/24 - Form 8-K
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- ACET's page on the SEC website